Antibodies to ticagrelor and methods of use

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9982061
SERIAL NO

14871111

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • MEDIMMUNE LIMITED

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Buchanan, Andrew Cambridge, GB 20 51
Inghardt, Tord Sodertalje, SE 32 171
Keyes, Feenagh Cambridge, GB 5 11
Newton, Philip Cambridge, GB 16 327
Nylander, Sven Sodertalje, SE 7 11
Penney, Mark Cambridge, GB 5 11

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 29, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 29, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00